EDIT
EDIT
NASDAQ · Biotechnology

Editas Medicine Inc

$2.23
-0.09 (-3.88%)
As of Mar 29, 10:36 PM ET ·
Analyst Consensus
Buy
20
Analysts
High
Coverage
Buy 12 60%
Hold 6 30%
Sell 2 10%
Price Target
Analyst Price Target +474.4% upside
Low Target $8.62
Average Target $12.81
High Target $14.59
Current Price $2.23
Current
$2.23
Target
$12.81
$8.62 $12.81 avg $14.59
Scenario Analysis
Bear Case
$8.62
286.5%
Low target
Base Case
$12.81
+474.4%
Avg target
Bull Case
$14.59
+554.3%
High target
Risk/Reward
1.9x
Balanced
Price in Context
52-Week High
$4.54
-50.9% from high
52-Week Low
$0.91
+145.0% from low
Target vs 52W High
$12.81
+182.3% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 39 69% $257.58 +19.8%
AMGN
Amgen Inc
Hold 42 50% $190.87 -46.0%
GILD
Gilead Sciences Inc
Strong Buy 38 79% $362.68 +158.5%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 -2.0%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.1%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 78% $102.31 -68.9%
INSM
Insmed Inc
Strong Buy 26 92% $143.40 -13.0%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -29.7%